Alexion Pharma (ALXN) Tops Q3 EPS by 28c, Revenues Beat; Boosts FY18 EPS/Revenue/Operating Margin Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alexion Reports Third Quarter 2018 Results
October 24, 2018 6:35 AM EDT3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase 3Q18 GAAP diluted EPS of $1.47 per share; non-GAAP diluted EPS of $2.02 per share Updated 2018 full-year guidance given the strength of the business Positive topline Phase 3 data for eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD); regulatory submissions planned for early 2019 Announced agreement to acquire Syntimmune and collaboration with Dicerna
BOSTON--(BUSINESS WIRE)--... More
